Intalight™ Achieves CE Marking for Dream OCT™ Progressive Imaging System

Intalight™ Achieves CE Marking for DREAM OCT™ Progressive Imaging System

Intalight™, a pioneering company in advanced ophthalmic technologies, recently announced a significant milestone in its journey by obtaining the CE marking for its cutting-edge imaging system, DREAM OCT™. This approval underscores the company's commitment to improving eye care through innovative solutions.

The CE marking signifies that DREAM OCT™ meets the essential health and safety requirements mandated by the European Union, enabling its commercial availability in European markets. This latest version of Optical Coherence Tomography (OCT) is a leap forward in ophthalmic imaging, promising enhanced capabilities for ophthalmologists working to improve patient outcomes.

DREAM OCT™ stands for Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. This advanced imaging platform delivers unparalleled quality in OCT images, catering to the diverse needs of eye care professionals and their patients alike.

"We are incredibly proud to receive the CE marking approval in Europe for our DREAM OCT system," stated Shawn Peng, President and Founder of Intalight. He emphasized how this achievement enables European ophthalmologists to access cutting-edge technology that significantly enhances patient care.

One of the standout features of the DREAM OCT™ system is its ultra-wide field capability, presenting sweeping scans up to 130 degrees in a single pass. This allows practitioners to obtain comprehensive angiographic OCT images that cover extensive areas of the eye. The system achieves remarkable scanning depths of 12mm, enabling detailed imaging of the choroid, retina, and a substantial portion of the vitreous space. Moreover, its capacity to capture images at great anterior scanning depths of up to 16.2mm facilitates thorough examination from the cornea through to the anterior vitreous, all in one scan. This is particularly beneficial in scenarios involving lens opacities and other challenges that may obscure visibility.

Companies like Intalight have specialized in developing technologies that address the pressing requirements of healthcare professionals. Bing Li, CEO and Co-founder of Intalight, highlighted how the DREAM OCT™ system is tailored for retinal specialists, comprehensive ophthalmologists, and their patients, providing highly detailed imaging capabilities that are crucial for effective diagnosis and treatment.

The system is already being recognized within the medical community, with over 160 peer-reviewed articles incorporating results obtained from DREAM OCT devices. This extensive validation further solidifies the system’s role as an essential tool in both clinical practice and research.

For Joe Garibaldi, the Chief Commercial Officer, this CE marking means there will be no waiting period in Europe. He conveyed excitement at the prospect of expanding the technological reach of Intalight across Europe and indicated hopes for eventual FDA approval in the United States. As a leader in clinically validated ultra-wide field OCT angiography, Intalight is continuing to collaborate with preeminent academic institutions and private Retina practices across the U.S., Europe, and Asia.

Company Background

Intalight Inc. was founded by a group of scientists and industry veterans from Silicon Valley, aiming to develop the most advanced ophthalmic technologies. Currently, the company operates three sites in Silicon Valley, along with operations in Shanghai and Luoyang. The combined strengths of imaging depth, rapid sweeping speed, extended scan range, precise lesion detection, and multimodal imaging capabilities embodied in DREAM OCT™ firmly position it as an indispensable device for numerous ophthalmologists in their daily clinical practices, as well as in the exploration of cutting-edge research within the field.

To learn more about Intalight and the capabilities of DREAM OCT™, please visit their website at Intalight and follow their social media channels on LinkedIn and Facebook.